CJC-1295 No DAC + Ipamorelin 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

GROW-H is a single combined 10 mg blend vial pairing CJC-1295 no DAC (modified GRF 1-29, a short-acting GHRH analog) with Ipamorelin (a selective ghrelin/GHS-R agonist). Together a GHRH analog and a GHRP are intended to amplify the body’s own pulsatile growth-hormone release. Both are unapproved research chemicals — neither is FDA-approved — and the long-term body-composition, recovery and sleep benefits of this blend are not validated by controlled human trials. Presented for research and educational use only.

One 10 mg combined vial. Add 3.0 mL bacteriostatic water → 3,333 mcg/mL (Standard), or 2.0 mL → 5,000 mcg/mL (Advanced).
300–1,200 mcg total blend once daily, on a 5-days-on / 2-days-off schedule, titrated upward across the cycle.
Doses are total blend. At 3,333 mcg/mL, 1 unit ≈ 33.3 mcg; at 5,000 mcg/mL, 1 unit = 50 mcg on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

One combined 10 mg vial — two dilution options for once-daily total-blend dosing

Advanced / Aggressive Approach (2 mL = 5,000 mcg/mL)

Phase / Week(s)	Total Blend Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	600 mcg (1× daily)	~12 units (0.12 mL)
Weeks 5–8	800 mcg (1× daily)	~16 units (0.16 mL)
Weeks 9–12	1,000 mcg (1× daily)	~20 units (0.20 mL)
Weeks 13–16 (optional)	1,200 mcg (1× daily)	~24 units (0.24 mL)

All doses below are stated as total blend (combined CJC-1295 no DAC + Ipamorelin). For a 10 mg blend the split is typically ~5 mg of each, though this is not labeled on the page; because both peptides share one vial, you cannot draw a single component separately. Run once daily on a 5-days-on / 2-days-off schedule to limit receptor desensitization.
Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg combined vial → 3,333 mcg/mL.
Typical daily range: 300–700 mcg total blend once daily, raised gradually across the cycle.
Easy measuring: At 3,333 mcg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe (units = mcg ÷ 33.33).
Reconstitute: Add 2.0 mL bacteriostatic water to the 10 mg combined vial → 5,000 mcg/mL. The smaller volume keeps higher doses comfortably above 10 units.
Typical daily range: 600–1,200 mcg total blend once daily, for researchers targeting higher doses.
Easy measuring: At 5,000 mcg/mL, 1 unit = 50 mcg on a U-100 syringe (units = mcg ÷ 50).
Frequency: one subcutaneous injection each day on a 5-on / 2-off pattern, titrating up as tolerated. Pairing a GHRH analog (CJC-1295 no DAC) with a GHRP (Ipamorelin) is intended to amplify natural pulsatile GH release; the acute synergy is pharmacologically reasonable, but these figures come from common supplier reference protocols, not from approved human dosing.

Reconstitution Steps

Draw 3.0 mL (Standard) or 2.0 mL (Advanced) of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution favors lower doses with simple math (1u ≈ 33.3 mcg); the 2.0 mL dilution suits higher doses while keeping units readable (1u = 50 mcg). Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections (5-on / 2-off) with gradual titration.

One combined 10 mg vial (CJC-1295 no DAC + Ipamorelin). At ~5 mg of blend used per week, a 10 mg vial covers roughly two weeks.
8 weeks: ~4 vials
12 weeks: ~6 vials
16 weeks: ~8 vials
Per injection: 1 syringe
8 weeks (5-on/2-off): ~40 syringes
16 weeks: ~80 syringes
Use 2.0–3.0 mL per 10 mg vial for reconstitution.
8 weeks (4 vials): ~12 mL → 2 bottles
16 weeks (8 vials): ~24 mL → 3 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (5-on/2-off): ~80 swabs → 1 box

Protocol Overview

A concise summary of the once-daily regimen, drawn from common supplier reference protocols.

▪Goal: Amplify the body’s own pulsatile GH release by pairing a GHRH analog (CJC-1295 no DAC) with a GHRP (Ipamorelin) — an acute, pharmacologically reasonable synergy; longer-term recovery and body-composition benefits are not established in controlled human trials.
▪Schedule: Once-daily subcutaneous injections, typically 5 days on, 2 days off, for 8–16 weeks.
▪Dose Range: 300–600 mcg total blend daily for most researchers, with advanced use reaching 1,000–1,200 mcg.
▪Reconstitution: 3.0 mL → 3,333 mcg/mL (Standard) or 2.0 mL → 5,000 mcg/mL (Advanced) per 10 mg vial.
▪Storage: Keep the dry vial frozen at −20 °C; once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses (all figures total blend).

▪Start: Begin at ~300 mcg once daily to gauge tolerability.
▪Titrate: Increase gradually every few weeks as tolerated.
▪Target: Reach about 600 mcg daily (Standard) or up to 1,000–1,200 mcg (Advanced) over the cycle.
▪Cycle Length: Typically 8–16 weeks, followed by a rest period to maintain receptor sensitivity.
▪Timing: Best on an empty stomach — morning or before bed — injected at a consistent time, rotating sites.

Storage Instructions

Correct storage is what preserves the peptides’ stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions.
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28–30 days; do not freeze the mixed solution.
▪Handling: Let frozen vials warm to room temperature before opening, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a sharps container afterward.
▪One combined vial: CJC-1295 no DAC and Ipamorelin share a single vial, so each dose draws both at once — you cannot measure or inject one component separately.
▪Empty stomach: Inject on an empty stomach and wait ~30 minutes before eating; site-rotate across abdomen, thighs and upper arms.
▪Monitoring: Track dose, site and observations weekly; discontinue if serious reactions occur.
▪Regulatory note: Both peptides are research chemicals, not FDA-approved (removed from 503A compounding Category 2 in Sept 2024; status in flux), and both are WADA-prohibited (class S2) for athletes.

How This Works

CJC-1295 no DAC (modified GRF 1-29) is a short-acting GHRH analog. It mimics growth-hormone-releasing hormone at the pituitary for a brief window (~30 minutes), nudging out a pulse of GH without driving a sustained, tonic rise in IGF-1.

Ipamorelin is a selective ghrelin / GHS-R agonist (a growth-hormone-releasing peptide, GHRP). It triggers a clean GH pulse with minimal effect on cortisol or prolactin.
Pairing a GHRH analog with a GHRP is intended to amplify pulsatile GH release beyond what either produces alone. This acute synergy is pharmacologically reasonable, but the longer-term body-composition, recovery and sleep benefits of this specific blend are not validated by controlled human trials — read such claims as hypotheses (research suggests, may).
Important: Neither CJC-1295 no DAC nor Ipamorelin is an approved medicine. Both are unapproved research chemicals presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support results alongside the protocol.

▪Nutrition: Keep a balanced, protein-rich diet to support muscle and tissue repair.
▪Exercise: Combine resistance and cardiovascular training, scaled to your goals.
▪Sleep: Aim for 7–9 hours; GH pulses are tightly linked to deep sleep.
▪Stress: Manage stress with evidence-based practices to support overall recovery.

Potential Benefits & Side Effects

Research suggests possible recovery, body-composition and sleep effects, but human evidence for this blend is limited and individual results vary.

▪Recovery & repair: Researchers report improved muscle recovery and repair, attributed to amplified GH pulses.
▪Sleep quality: Anecdotal reports of deeper, more restful sleep.
▪Body composition: May support lean-mass and fat-loss goals over a cycle.
▪Note on humans: These benefits are not validated by controlled trials of this CJC-1295 no DAC + Ipamorelin blend.
▪Water retention & flushing: Mild water retention, headaches or transient flushing can occur.
▪Injection-site reactions: Mild redness, tenderness or irritation; rotating sites helps.
▪Unknown long-term profile: Human safety data for this blend is limited, so caution and monitoring are advised.
▪Sport restriction: Both peptides are WADA-prohibited (S2) for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance.

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully.
▪Draw the intended total-blend dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin).
▪Skip aspiration for subcutaneous shots — it isn’t needed.
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy.
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for the GROW-H 10 mg blend (CJC-1295 no DAC + Ipamorelin).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for CJC-1295 No DAC + Ipamorelin 10mg.

CJC-1295 no DAC & Ipamorelin (10mg Blend Vial) Dosage Protocol Open source
1 Journal of Clinical Endocrinology & Metabolism Teichman et al. — CJC-1295 (a GHRH analog) prolongs and elevates GH and IGF-1 in healthy adults. View Source ↗ Open source
2 Endocrine / GHRH pharmacology Modified GRF 1-29 (CJC-1295 no DAC) as a short-acting GHRH analog and its pulsatile GH effect. View Source ↗ Open source
3 European Journal of Endocrinology Raun et al. — Ipamorelin, a selective ghrelin/GHS-R agonist and GH secretagogue. View Source ↗ Open source
4 GHRH + GHRP synergy Studies on combined GHRH and GH-releasing peptide administration amplifying pulsatile GH secretion. View Source ↗ Open source
5 U.S. FDA 503A bulk drug substances — peptides removed from compounding Category 2 (2024); CJC-1295 and Ipamorelin are not FDA-approved. View Source ↗ Open source
6 World Anti-Doping Agency Prohibited List — peptide hormones and GH secretagogues / releasing factors (class S2). View Source ↗ Open source
7 CDC / clinical guidance Best practices for safe subcutaneous injection technique and sharps handling. View Source ↗ Open source
8 Peptide handling guidance Reconstitution and cold-chain storage practices for lyophilized research peptides. View Source ↗ Open source
9 Prime Lab Peptides GROW-H 10 mg blend (CJC-1295 no DAC + Ipamorelin) product page — purity specifications and COAs. View Source ↗ Open source